Copaxone

Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA) last week reported a 19-percent drop in Q3 revenues, stung by generic competition to its multiple sclerosis drug Copaxone, price erosion at its U.S. generic business, and certain product divestments. Non-GAAP income fell a less-than-expected to 68...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced a restructuring program late last year that is now showing some signs of early success, according to Credit Suisse. The Analyst Credit Suisse's Vamil Divan upgraded Teva's stock rating from Neutral to Outperform with a...

Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...

After a turbulent 2017, Mizuho analysts now see upside potential for Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock. The Analyst Mizuho Securities USA's Irina Koffler upgraded Teva's stock rating from Neutral to Buy with a price target boosted from $16 to $23. The...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. The Analyst JPMorgan's Chris Schott downgraded Teva's stock rating from Neutral...

Analysts at Deutsche Bank see a scenario in which Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock can move higher from its current levels but are simultaneously no longer recommending investors be buying the stock. The firm's Gregg Gilbert downgraded Teva's stock from Buy...

The U.S. Food and Drug Administration's approval of Mylan N.V. (NASDAQ: MYL)'s generic version of Copaxone for the treatment of relapsing multiple sclerosis should be seen as a "clear negative" for Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s Glatopa franchise, analysts at Baird said. The firm's...

Mylan N.V. (NASDAQ: MYL) announced Tuesday that the FDA has approved its Abbreviated New Drug Application for the first generic for Copaxone. Mylan shares were up 19 percent to $38.75. Wells Fargo raised Mylan's price target from $30 to $32, and maintained the rating at Market Perform....

The FDA dealt yet another blow to struggling Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) investors by approving rival Mylan N.V. (NASDAQ: MYL)’s generic version of Teva’s Copaxone multiple sclerosis drug. Analysts say generic competition was not factored into Teva’s...

Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were under heavy selling pressure Wednesday morning after the U.S. Food and Drug Administration granted approval for a rival product. The FDA granted approval to Mylan N.V. (NASDAQ: MYL) to sell a generic version of Teva's Copaxone...

Shares of Mylan N.V. (NASDAQ: MYL) traded higher by more than 13 percent Wednesday morning after the U.S. Food and Drug Administration granted approval for the company's generic version of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s Copaxone. Copaxone, a therapy that is intended...

Ahead of an expected uptick in news flow next month, Credit Suisse reviewed its ratings and price targets on the shares of several pharma companies, keeping in mind the fiscal year 2017 and the first-half of 2018. The firm downgraded shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:...

The health care sector, the third-largest sector weight in the S&P 500, is bouncing back in an impressive fashion this year after posting its first annual loss last year since 2008. While diversified health care exchange traded-funds are up 14 percent or more year to date, some more focused...

Based on the nearly 25-percent decline in Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock price on Thursday, some investors and analysts have legitimate concerns over the company's earnings report and outlook. Among those on Wall Street who share this concern include...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s earnings report brought mostly bad news for investors, which resulted in an 18-percent plunge in the stock Thursday morning. But not all analysts are ready to throw in the towel, as Credit Suisse's Vamil Divan maintains an Outperform...